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Background: TDP-43, a multi-functional DNA/ RNA-binding protein encoded by the TARDBP gene, has emerged as
a major patho-signature factor of the ubiquitinated intracellular inclusions (UBIs) in the diseased cells of a range of
neurodegenerative diseases. Mutations in at least 9 different genes including TARDBP have been identified in ALS
with TDP-43 (+)-UBIs. Thus far, the pathogenic role(s) of the more than 30 ALS-associated mutations in the TARDBP
gene has not been well defined.
Results: By transient DNA transfection studies, we show that exogenously expressed human TDP-43 (hTDP-43),
either wild type (WT) or 2 different ALS mutant (MT) forms, could cause significantly higher apoptotic death rate of
a mouse spinal motor neuron-like cell line (NSC34) than other types of cells, e.g. mouse neuronal Neuro2a and
human fibroblast HEK293T cells. Furthermore, at the same plasmid DNA dose(s) used for transfection, the
percentages of NSC34 cell death caused by the 2 exogenously expressed hTDP-43 mutants are all higher than that
caused by the WT hTDP-43. Significantly, the above observations are correlated with higher steady-state levels of
the mutant hTDP-43 proteins as well as their stabilities than the WT.
Conclusions: Based on these data and previous transgenic TDP-43 studies in animals or cell cultures, we suggest
that one major common consequence of the different ALS-associated TDP-43 mutations is the stabilization of the
hTDP-43 polypeptide. The resulting elevation of the steady state level of hTDP-43 in combination with the relatively
low tolerance of the spinal motor neurons to the increased amount of hTDP-43 lead to the neurodegeneration and
pathogenesis of ALS, and of diseases with TDP-43 proteinopathies in general.
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The TAR-DNA-binding protein 43 (TDP-43)-encoding
gene, TARDBP, is well conserved among the multicellular
organisms from C. elegans to human [1,2]. Of the multiple
isoforms encoded by the TARDBP gene, the 43 kDa
TDP-43 protein is the most abundant one expressed in all
tissues [3,4], mainly in the nucleus but some also residing
in the cytoplasm [4,5]. TDP-43 appears to be a general
transcription repressor [3,5,6], a splicing factor [7,8], and a
neuronal activity-responsive factor [4]. Not surprisingly,* Correspondence: ckshen@imb.sinica.edu.tw
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reproduction in any medium, provided the orintact TARDBP gene is indispensible for normal early
development of the mouse embryos [9-12]. Lately, TDP-43
has emerged as the major patho-signature protein of the
ubiquitinated intracellular inclusions (UBIs) in the diseased
brain/ neuron cells of a range of neurodegenerative
diseases, two major ones being the frontotemporal lobar
degeneration with ubiquitin-positive, tau- and α-synuclein -
negative inclusions (FTLD-U) and amyotrophic lateral
sclerosis (ALS) [13-15]. Biochemical analyses have
revealed that human TDP-43 (hTDP-43) is promiscuously
modified/ processed in the affected regions of the brains
and spinal cords of the FTLD-U and ALS patients,
respectively [13-15]. Loss-of-function of TDP-43 as well. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modifications of TDP-43, have been suggested to lead to
the pathogenesis of FTLD-U and as ALS with the TDP-43
(+) UBIs [6,15-18 and references therein].
The molecular and cellular basis for the pathogenesis
of either ALS or FTLD-U is poorly understood yet.
Mutations in 11 different genes, including the long
studied superoxide dismutase 1 (SOD 1) and TARDBP,
have been identified to be associated with 10% of ALS
[19], which is a disease with age-dependent degeneration
of the spinal cord motor neurons [20]. Furthermore, the
majority of the ALS cases, including those the disease
genes of which have not been identified yet, are signalized
with the TDP-43(+)-UBIs [21]. Interestingly, more than 30
different ALS-associated TARDBP mis-sense substitutions
have been identified, almost all of which are mapped in
the glycine-rich domain of TDP-43 [15,16,22]. A number
of DNA transfection/ microinjection experiments in cell
cultures or cell lines have been carried out to analyze the
cyto-toxicities of different ALS-associated hTDP-43 mutants
in comparison to the wild type [23-27]. For instance,
Q331K and M337V accelerate spontaneous hTDP-43
aggregation in yeast cells [23]. On the other hand, while
both the wild type hTDP-43 and 3 mutant forms of
hTDP-43 (A315T, G348C, and A382T) induce death of
primary motor neurons but not cells from Neuro2a and
COS cell lines, the mutant forms are more potent than
the wild type hTDP-43 in the induction of neuron death
[24]. hTDP-43A315T is also more toxic to the primary
rat cortical neurons than the wild type hTDP-43
[25]. Furthermore, hTDP-43Q331K and TDP-43M337V
induce oxidative injury of the motor neuron-like
NSC34 cells [26]. One unanswered question from
these studies is why, in general, the ALS-associated
mutants of hTDP-43 are more cyto-toxic than the
wild type hTDP-43. Notably, in most, if not all, of
the above mentioned cell culture and cell line studies, the
relative cellular levels of the exogenous proteins were not
quantified and compared between the wild type and
mutant hTDP-43.
In the following, we show that two randomly chosen
ALS mis-sense mutations of the TARDBP gene both
increase the stability of the TDP-43 polypeptide in motor
neuron-like cells as well as in non-motor neuron cells. In
addition, the mutant hTDP-43 polypeptides as well as the
wild type hTDP-43 induce significant apoptosis of motor
neuron-like cells, but much less so in non-motor neuron
cells, in a dose-dependent manner. Thus, the major role
of the ALS-associated hTDP-43 mutations appears to be
the enhancement of the steady-state level of hTDP-43
through stabilization of the polypeptide in the spinal
motor neurons, which have a low tolerance to the elevated
cellular level of TDP-43 in comparison to the non-motor
neuron cells.Methods
Construction of expression plasmids
Wild type (WT) human hTDP-43 with addition of a Myc
epitope tag to its 3’-end was generated by PCR of human
brain cDNA using the following primers: forward, 5'-CCG
CTC GAG CGG ATG TCT GAA TAT ATT CGG GTA
AC -3'; reverse, 5'-TCT AGA GCT ACA GAT CCT CTT
CCG AGA TGA GTT TTT GTT CCA TTC CCC AGC
CAG AAG AC-3'. The A315T and N390D mutations were
introduced into the WTcDNA by site-directed mutagenesis
using the QuikChange® Site-Directed Mutagenesis Kit
(Strategene). The three hTDP-43 cDNAs were first
cloned into the pGEM-T vector (Promega, Madison, WI).
Following sequence confirmation, the cDNA inserts were
subcloned into the XhoI/ XbaI sites of a pEF vector. Ex-
perimental research that is reported in the manuscript
was performed with the approval of an appropriate ethics
committee.
Antibodies
The commercial antibodies used in this study included a
rabbit anti-TDP-43 polyclonal antibody (pAb) raised against
a.a 1–260 of human TDP-43 and recognizing human as
well as mouse TDP-43 (Gene Tex), a human specific mouse
monoclonal antibody (mAb) against the same TDP-43
sequence (2E2-D3) (Abnova), anti-Myc mAb (LTK),
anti-α-tubulin (Sigma), anti-cleaved caspase 3 (Asp175)
(Ac-cap3) (Cell Signaling), and anti-Hsp70 (Chmicon).
Cell cultures and DNA transfection
NSC34 cells were maintained in DMEM (Invitrogen)
supplemented with 10% FBS (Invitrogen) and 1% antibi-
otics (100 IU/mL penicillin and 100 g/mL streptomycin).
Neuro2a cells were maintained in MEM (Invitrogen)
supplemented with 10% FBS (Invitrogen), 1% antibiotics,
and 1% sodium pyruvate (Invitrogen). SHSY5Y cells were
maintained in DMEM/F12 (Invitrogen) with 10% FBS
(Invitrogen), 1% antibiotics, and 1% sodium pyruvate
(Invitrogen). The cells were transfected with the empty
pEF vector and the expression plasmids, respectively, using
Lipofectamine 2000 transfection reagent (Invitrogen)
following the manufacturer’s protocol. The amount of
the plasmid DNA used in each transfection was kept at
20 μg/106 cells by supplement with the pEF vector
DNA. After transfection for different hrs, the cells were
harvested and analyzed by Western blotting. In general,
under the conditions used by us, the transfection efficien-
cies of NSC34, Neuro2A, SHSY5Y, and HEK293 were
approximately 50%, 70%, 70%, and 90%, respectively.
Cell death assay with use of Caspase-Glo 3/7
After incubation with the transfectants, the cells were
split and seeded with two different densities, 2 × 103
cells/well and 8 × 103 cells/well, and allowed to grow for
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were at 30% confluency before the assay. For the assay,
Caspase-Glo 3/7 reagent (Promega) was added to all
the wells in a 1:1 ratio following the manufacturer's
instructions. Cells with addition of 5 μM staurosporine
(0.1% final DMSO; Sigma) for 6 hr were used as a positive
control [28]. After shaking at room temperature for 30
min, the lysates were analyzed with an Microplate Reader
(Vector). A total of 3 replicates were performed. To
determine the fold changes of caspase 3/ 7 activities,
four independent experiments were carried out. The data
were expressed as means ± SD. The differences in the
caspase 3/ 7 activities among the variants were assessed
by the ANOVA test. An unpaired two-tailed Student’s
t-test was then used to obtain the p values associated
with comparisons between the MT and WT.
Cell death assay by immunofluorescence staining
The cells were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS), permeabilized with
0.1% Triton X-100 (Sigma) in PBS for 5 min, blocked
with 10% donkey serum in PBS for 2 hr, and incubated
overnight at 4°C with the primary antibodies anti-
hTDP-43 (2E2-D3), anti-Myc, and anti-cleaved caspase 3,
respectively . The primary antibodies were visualized with
secondary antibodies conjugated with Alexa Fluor 488 or
Alexa Fluor 561 (Molecular Probe), and the nuclei were
detected using DAPI (4,6-diamino-2-phenylindole). The
patterns of immunofluorescence staining were analyzed in
a LSM710 confocal microscope (Zeiss). For quantification
of cleaved caspase-3 positive cells, several random fields/
sample were analyzed and the percentages of transfected
cells displaying anti-cleaved caspase 3 staining signals and
apoptotic nuclei were calculated (N=150 cells, duplicate in
one experiment). To determine the percentages of dead
cells, four independent experiments were carried out. The
data were expressed as means ± SD. The differences in %
of the Ac-cap 3-positive cells among the variants were
assessed by the ANOVA test. An unpaired two-tailed
Student’s t-test was then used to obtain the p values
associated with comparisons between the MT and WT.
Western blot analysis
Cells were lysed in RIPA buffer (0.1% SDS, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 5mM EDTA, 150mM
NaCl, 50mM Tris-HCl, pH 8.0) supplemented with
protease inhibitors (Roche) and phosphatase inhibitors
(Sigma). The protein concentrations of the lysates were
measured using the Bio-Rad protein assay reagent on
a Beckman Coulter DU-800 machine. The lysates were
then resolved by SDS–PAGE and immunoblotted with the
indicated antibodies. Quantification of the immunoblot
band intensities was performed with use of the Image J
software (NIH). There independent experiments on eachcell line were carried out for densitometry analysis. The
data were expressed as means ± SD. The differences in
the relative levels of hTDP-43 among the variants were
assessed by the ANOVA test. An unpaired two-tailed
Student’s t-test was then used to obtain the p values
associated with comparisons between the MT and WT.
Protein degradation analysis
Cells were transfected with different expression plasmids
encoding Myc-tagged versions of WT hTDP-43 and the
two MT hTDP-43. Cycloheximide (50 μg/ mL; Sigma)
was added to the media at 40 hr post-transfection. At
various time points thereafter, the transfected cells were
lysed and the amounts of the Myc tagged TDP-43
proteins were measured by Western blot analysis using
the anti-hTDP-43 antibody (2E2D3) or anti-Myc antibody
(LTK). Four independent experiments on each cell line
were carried out for densitometry analysis. The data were
expressed as means ± SD. The differences in relative levels
of hTDP-43 among the variants were assessed by the
ANOVA test. An unpaired two-tailed Student’s t-test was
then used to obtain the p values associated with compari-
sons between the MT and WT.
Statistical analysis
The data obtained from independent experiments are
expressed as the mean ± S.D.. The differences among the
variants were assessed by the ANOVA test. An unpaired
two-tailed Student’s t-test was then used to obtain the
p values associated with comparisons between the MT
and WT.
Results and discussion
Overexpression of Wild Type (WT) or Mutant (MT) Human
TDP-43 (hTDP-43) induced apoptotic death of motor
neuron cells
To examine the relative cytotoxicities of WT and MT
hTDP-43 in motor neuronal cells and non-motor neuronal
cells, respectively, plasmids encoding the WT hTDP-43
and hTDP-43 carrying two different ALS-associated
mutations (A315T and N390D) (Figure 1A) were transi-
ently transfected into mouse NSC34, mouse Neuro2a,
human HEK293T, and human SHSY5Y cells. Of these
cell lines, NSC34 was established by fusion of the
embryonic mouse spinal cord cells, which were enriched
in the motor neurons, with mouse neuroblastoma cells
[29]. It exhibited a number of motor neuron properties
and was used widely as a cellular model system for
motor neuron studies [30]. On the other hand, the
differentiated neuron-like Neuro2a was established from
a spontaneous neuronal tumor of a strain A albino
mouse [31]. SHSY5Y cells was an human neuroblastoma
cell line [32]. HEK 293T was an embryonic human kidney
fibroblast cell line [33]. The two ALS-associated hTDP-43
Figure 1 Immunofluorescence staining analysis of NSC34 and
Neuro2a cells overexpressing WT and MT hTDP-43. (A) Physical
maps showing the domains of human TDP-43 (hTDP-43) and mouse
TDP-43 (mTDP-43). NLS, nuclear localization signal; NES, nuclear
export signal; GR, glycine-rich sequence; GQN, glycine (G), glutamine
(Q) and/ or asparagine (N)-rich sequence. For hTDP-43, the cDNA
inserts in the 3 expression plasmids encoding the WT and the two
mutant forms of hTDP-43 are shown. The positions of the
nucleotide substitutions are indicated by the stars.
(B) Representative photographs showing the immunofluorescence
staining patterns of transfected cells. NSC34 (upper two rows) and
Neuro2a (lower two rows) cells were transfected with plasmids
expressing the WT hTDP-43 and hTDP-43A315T, respectively, and
analyzed by immunofluorescence staining at 48 hr post-transfection
with use of the 2E2D3 antibody recognizing hTDP-43 and DAPI
staining the nucleus. Note the predominant nuclear localization of
the exogenous WT and MT hTDP-43 in both types of cells. Scale bar,
10 μm.
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more than one patient and by more than one group
[15,16]. As seen in Figure 1B, the sub-cellular localization
of the exogenous hTDP-43 was mainly nuclear in both
transfected NSC34 and Neuro2a cells. Similar patterns
were observed for transfected HEK 293T and SHSY5Y
cells (data not shown). Consistent with the previous studies
[24,34], the WT or MT hTDP-43 could be seen to form
cytosolic aggregates in only a few percent of the transfected
cells (data not shown).
To examine the apoptotic cell death induced by
overexpression of the WT hTDP-43 in comparison tothe MT hTDP-43, we measured activities of the effector
apoptotic caspases 3 and 7 of NSC34 (Figure 2A, left
panel), Neuro2a (Figure 2A, right panel), and HEK 293T
cells (data not shown) using a luminescent assay [35]. As
seen, transfection of 106 cells with 5 μg of plasmids
overexpressing WT hTDP-43 (Figure 2A) or wild type
mouse TDP-43 (mTDP-43) (Additional file 1: Figure S1)
had little effect on the caspase 3/ 7 activities. On the
other hand, NSC34 cells overexpressing the MT hTDP-
43 at 72 hr, but not 24 hr, post-transfection exhibited
45-70% increases of the activities of caspase 3/ 7 in
comparison to the vector control (left panel, Figure 2A).
In contrast, the caspase 3/ 7 activities of Neuro2a cells
overexpressing the MT hTDP-43 increased by only little
(right panel, Figure 2A). Result of transfected HEK 293T
cells was similar to Neuro2a (data not shown). Taken
together, at the same dose (5 μg/ 106 cells) of the expression
plasmid(s) used for transfection, overexpression of the
two MT hTDP-43 forms caused a motor neuronal cell
type-specific cytotoxicity significantly higher than that by
the WT hTDP-43.
Motor neuronal cell-specific apoptotic death induced by
both MT and WT hTDP-43 were dose-dependent
To examine whether the neurotoxicity of NSC34 cells
caused by the overexpressed MT hTDP-43 was dose-
dependent, we transfected NSC34 and Neuro2a cells
with different amounts of the individual expression
plasmids. The extents of apoptotic cell death were then
analyzed by immunostaining with anti-cleaved caspase 3.
Interestingly, MT hTDP-43 as well as WT hTDP-43
caused apoptotic cell death of the NSC34 cells in a dose-
dependent manner, with the proportion of cleaved
caspase 3-positive cells increased from 4-6% at the dose
of 2.5 μg plasmid/ 106 cells to 15-19% at 10 μg plasmid/
106 cells (upper left panel, Figure 2B). Furthermore, at
each dose used for transfection, both MT hTDP-43
forms showed higher toxicities than the WT. Also, the
differences of the effects between MT and WT hTDP-43
increased as higher amounts of the expression plasmids
were used for transfection (upper left panel, Figure 2B).
Similar to Figure 2A, overexpression of either MT or
WT form of hTDP-43 caused much smaller increase
(~4%) of the cell mortality of Neuro2a (upper right
panel, Figure 2B) or HEK 293 cells (data not shown).
Interestingly, overexpression of the wild type mTDP-43
also caused the selective neuronal apoptosis of the NSC34
cells in comparison to Neuro2a cells (Additional file 2:
Figure S2). These data suggested that overexpression of
either WT or MT hTDP-43 could cause significantly
higher cytotoxicity in the motor neuronal-type cells than
non-motor neuron cells. For some reason, however, the
MT hTDP-43 appeared to be more toxic to NSC34 cells
than the WT hTDP-43 or WT mTDP-43.
Figure 2 Apoptotic assays of transfected NSC34 and Neuro2a cells. (A) Comparison of apoptotic death induced by exogenous WT and MT
hTDP-43. Cell death was assayed by measurement of the activities of caspase 3/ 7 at 24 hr and 72 hr post-transfection with the expression
plasmids (5 ug/ 106 cells). Mock, cells without transfection; C, cells transfected with the pEF vector; Stau. 5 uM, cells treated with 5 uM of
staurosporine for 6 hr to induce apoptosis. The folds of the caspase activities relative to that of the Mock sample were calculated and shown.
Note the significant increase of the caspase 3/ 7 activities in NSC34 cells (left panel), but not Neuro2a cells (right panel), induced by the two MT
hTDP-43 forms at 72 hr post-transfection. (B) Comparison of plasmid dose-dependent apoptotic death induced by exogenous WT and MT hTDP-
43. Apoptotic cell death was determined by immunofluorescence staining of cleaved caspase 3. The extents of apoptotic cell death of NSC34
cells and Neuro2a cells at 72 hr post-transfection with different amounts of the expression plasmids were assayed by immunofluorescence
staining with the antibodies 2E2D3 and Ac-cap 3. Means of three independent experiments (S.D.) are plotted in the upper 2 panels, with the % of
hTDP-43-positive cells that are also Ac-cap 3-positive as a function of the doses of transfection. Approximately 1% of cells transfected with the
pEF vector were Ac-cap3 positive (◆ in the two plots). Representative photographs are shown below the plots, with the apoptotic nuclei/ cleaved
caspase 3-positive cells indicated by the arrowheads. For both the NSC34 and Neuro2a sets, two Ac-cap 3-positive cells (the boxed areas) are
magnified for better visualization. Scale bar, 10 μm. *, p<0.05; **, p<0.01; ***, p<0.001.
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NSC34 as well as in Neuro2a Cells
The relatively higher death incidence of NSC34 cells as
caused by MT hTDP-43 than the WT hTDP-43 (Figure 2B)
could be due to that ALS-associated TDP-43 mutations
affecting certain motor neuronal cell-specific functions of
hTDP-43 or cellular pathways. Alternatively, these muta-
tions might exert their effects by elevating the steady-statelevel of the MT hTDP-43 through stabilization of the
protein. Significantly, when the total cellular extracts of
transfected cells were analyzed by Western blotting, the
steady-state levels of the two MT hTDP-43 were indeed
higher than the WT TDP-43, and this was the case over a
range of the amounts of plasmid DNA used for transfection
(left panel of Figure 3A and Table 1). Similar pattern was
observed when the extracts of transfected Neuro2a cells
Figure 3 hTDP-43 protein dose-dependent apoptotic death of NSC34 cells. (A) Higher levels of MT hTDP-43 than WT hTDP-43 at the same
dose(s) of DNA transfection. NSC34 and Neuro2a cells were transfected with different doses (μg/ 106 cells) of the expression plasmids. At 72 hr
post-transfection, the levels of the exogenous hTDP-43 expressed were compared by Western blotting using the anti-hTDP-43 antibody 2E2D3,
with the mouse Hsp70 level as the internal control. The means of the relative levels of hTDP-43 obtained from three independent experiments
(S.D.) are then plotted in the 2 panels, with the level of the WT hTDP-43 in cells with the transfection dose of 20 μg DNA/ 106 cells as 100.
Note the higher levels of the MT hTDP-43 than WT hTDP-43 in both NSC34 and Neuro2a cells at all doses of transfection. *, p<0.05; **, p<0.01;
***, p<0.001. (B) The % of transfected cells that were cleaved caspase 3-positive as a function of the relative amounts of hTDP-43. The plots were
derived from the combined data of Figures 2 and 3A. The amounts of hTDP-43 in NSC34 cells or Neuro2a cells transfected with 20 μg of
pEF-hTDP-43N390D are assigned the value of 1.
Table 1 Levels of exogenous hTDP-43 proteins relative to
the endogenous mTDP-43 in transfected cells*
Plasmid DNA amount (μg) used for
transfection of 106 cells
1.25 2.5 5 10 20
NSC34
WT 0.26 0.56 0.73 0.87 1.1
A315T 0.54 0.77 0.80 1.0 1.3
N390D 0.61 0.86 0.93 1.3 1.5
Neuro2a
WT 0.29 0.49 0.86 1.4 1.7
A315T 0.44 0.65 1.1 1.6 1.9
N390D 0.50 0.89 1.2 1.6 2.2
* The levels of the exogenous hTDP-43 proteins relative to the endogenous
mTDP-43 were measured first by Western blot analysis using the Gene Tex
antibody recognizing both hTDP-43 and mTDP-43. The ratio of the intensity of
the exogenous hTDP-43 to that of the endogenous mTDP-43 at each dose of
the transfection was estimated and then calibrated against the average
transfection efficiencies of the cells (50% for NSC34 and 70% for
Neuro2a cells).
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parallel to Additional file 2: Figure S2, the dose dependence
of the steady state level of WT mTDP-43 in transfected
NSC34 or Neuro2a cells was similar to WT hTDP-43
(Additional file 3: Figure S3).
Since both the cytotoxicity of NSC34 cells caused by
MT hTDP-43 (Figure 2B) and their steady-state levels
(Figure 3A) were higher than WT hTDP-43 at the same
dose(s) of DNA transfection, we speculated that the
differences of cytotoxicities as caused by the MT and
WT hTDP-43 might reflect mainly the differences of the
steady-state levels of the proteins, instead of the sequence
differences of the polypeptide per se. Indeed, as seen in
the left panel of Figure 3B, the NSC34 cell death caused
by the exogenous hTDP-43 proteins increased as a function
of the relative amounts of the proteins, irrespective of
whether the protein was the WT or the MT forms. As
expected from the data of Figure 2B, the relatively
lower cytotoxicity of the Neuro2a cells caused by the
exogenous hTDP-43 remained similar over a range of
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cells (right panel, Figure 3B).
We then examined whether the ALS-associated
mutations stabilized hTDP-43 in NSC34, Neuro2a, and
SHSY5Y cells. For this, we carried out cycloheximide
chase experiments [36] (also see the experimental details
in Methods) in these three types of cells. 106 of the cells
were transfected with 2.5 μg of the individual expression
plasmids and then split into different aliquots at 20 hr
post-transfection. These aliquots of cells were allowed to
adhere for another 20 hr and then each aliquot was
treated with cycloheximide for a different period of time.
As exemplified in the Western blots in Figure 4, the
amounts of the WT hTDP-43 in different types of
the transfected cells, i.e. NSC34 (Figure 4A), Neuro2a
(Figure 4B), SHSY5Y (Figure 4C), and HEK293T
(data not shown) were significantly lower than those
of the two MT hTDP-43 forms at each of the time
points of cycloheximide treatment. This corresponded toFigure 4 Increased stabilities of hTDP-43 polypeptides with ALS-asso
transfected NSC34 (A), Neuro2a (B), and SHSY5Y (C) cells were measured b
Western blots of the exogenous WT hTDP-43 and MT hTDP-43A315T in trans
amounts of hTDP-43 at different hr of cycloheximide treatment are plotted
chase experiments are used for the plots. p<0. in NSC34, Neuro2a, and SHSincreases of the half-life of hTDP-43, as the result of the
ALS mutations, by approximately 2 to 4 hrs (Figure 4A),
6 to 8 hrs (Figure 4B), and 6 to 8 hrs (Figure 4C),
respectively. The stabilization of hTDP-43 by the ALS
mutations was in consistency with the higher steady-state
levels of the MT hTDP-43 proteins than the WT hTDP-43
in transfected NSC34 cells (Figure 3).
Both WT and MT hTDP-43 induced motor neuron cell
death in a dose- dependent manner
The cell type-independent stabilization of hTDP-43 by
A315T and N390D, as shown above, might be a general
effect of most of the ALS-associated TDP-43 mutations.
3 others (Q298S, Q331K, and M337V) have been shown
to stabilize hTDP-43 in HeLa cells and in primary fibro-
blast culture from a human patient [37]. Also, 5 other
ALS-associated mutations (G298S, Q343R, G348C,
N352S, and A382T) increased the protein half-life of
hTDP-43 in Neuro2a cells [38]. In the latter study, it wasciated mutations. The stabilities of the exogenous hTDP-43 in
y cycloheximide chase experiments as described in Methods. The
fected cells are shown as the examples of analysis. The relative
in the upper two panels. The mean values of 3 different sets of the
Y5Y cells.
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was correlated with an early disease onset, but not related
to the detergent insolubility and subcellular localization
of hTDP-43 [38] This effects provides a reasonable
explanation for the appearing-to-be higher motor
neuron cyto-toxicity of the MT hTDP-43 forms than the
WT when the cell death data from DNA transfection
experiment(s) using the same amount(s) of the expression
plasmids are compared (Figure 2B). In other words,
overexpression of hTDP-43 is sufficient to cause dose-
dependent apoptotic deaths of the motor neuronal NSC34
cells, irrespective of whether the overexpressed hTDP-43
is WT or carrying ALS-associated mutations (Figure 2B
and 3B). With respect to the dose dependence, increase of
the cellular level of the TDP-43 protein, with exogenous
expression of either WT or MT forms of hTDP-43, by
50-200% (Table 1) would induce 5-20% of the transfected
NSC34 cells to undergo apoptotic death (Figure 2B).
In interesting parallel with the dose-dependence of the
cytotoxicity of hTDP-43 as derived from this study, pre-
vious transgenic mice [39-44] and transgenic Drosophila
[45-47] experiments have suggested that elevation of the
level of TDP-43, whether mutant forms or the wild type,
is sufficient to cause TDP-43 proteinopathies. Also,
overexpression TDP-43 in cultured human [48] and mouse
cells [24,49] induced cytotoxicity. These transgenic cell
culture and animal studies are in interesting correlation
with the finding of elevated levels of hTDP-43 expression
in some cases of ALS and FTLD-U [50,51]. Thus, the
steady-state level of TDP-43 could be one determining
factor for the occurrence and/ or progression of
neurodegeneration in TDP-43 proteinopathies. Finally,
since the stabilization of hTDP-43 by the ALS-associated
mutations occurs in all the cell types that we have tested,
it is likely that motor neuronal cells have a relatively low
tolerance to the elevated amount of hTDP-43 when
compared to other types of cells.
Take together all of the above, we suggest that patho-
genesis of ALS could be due to the selective neurotoxicity
of the spinal motor neurons caused by elevated level of
hTDP-43, which in turn results from mis-regulation of the
hTDP-43 metabolism due to different ALS-associated
gene mutations including those within the TARDBP gene
itself. How the ALS-associated mutations in hTDP-43
stabilize the protein and why the spinal motor neurons
have a relatively low tolerance to the elevated level of
TDP-43 remain to be investigated.
Conclusions
In conclusion, based on our data and previous transgenic
TDP-43 studies in animals or cell cultures, we suggest that
one major common consequence of the different ALS-
associated TDP-43 mutations is the stabilization of the
hTDP-43 polypeptide. The resulting elevation of thesteady state level of hTDP-43 in combination with the
relatively low tolerance of the spinal motor neurons to the
increased amount of hTDP-43 lead to the neurodegeneration
and pathogenesis of ALS, and of diseases with TDP-43
proteinopathies in general.
Additional files
Additional file 1: Figure S1. Comparison of apoptotic deaths of cells
with exogenous expression of WT hTDP-43 and mTDP-43. Apoptotic cell
death was assayed by the activities of caspase 3/ 7 at 24 hr and 72 hr
post-transfection of NSC34 and Neuro2a cells with plasmids expressing
hTDP-43 and mTDP-43, respectively (5 ug/ 106 cells), as described in the
legend of Figure 2A. Mock, cells without transfection; C, cells transfected
with the pEF vector; Stau. 5 uM, cells treated with 5 uM of staurosporine
for 6 hr to induce apoptosis. The folds of the caspase activities relative to
that of the Mock sample were calculated and shown. Note the lack of
effect on the caspase 3/ 7 activities by the exogenously expressed hTDP-
43 or mTDP-43. The differences in the caspase 3/ 7 activities among the
variants were assessed by the ANOVA test.
Additional file 2: Figure S2. Comparison of the plasmid dose-dependent
apoptotic deaths induced by exogenous hTDP-43 and mTDP-43. Apoptotic
deaths of transfected NSC34 cells and Neuro2a cells at 72 hr post-transfection
with different amounts of the expression plasmids were assayed by
immunofluorescence staining with the antibodies anti-Myc and Ac-cap 3, as
described in the legend of Figure 2B. Means of three independent
experiments (S.D.) are plotted in the upper 2 panels, with the % of hTDP-43
-positive cells that are also Ac-cap 3-positive as a function of the doses of
transfection. Approximately 1% of cells transfected with the pEF vector were
Ac-cap3 positive (* on the y axes of the two plots). Representative
photographs are shown below the plots. Scale bar, 10 μm. The differences in
% of the Ac-cap 3-positive cells among the variants were assessed by the
ANOVA test.
Additional file 3: Figure S3. Expression plasmid dose-dependent
increase of hTDP-43 and mTDP-43 in trasnfected NSC34 and Neuro2a
cells. NSC34 and Neuro2a cells were transfected with different doses
(μg/ 106 cells) of the appropriate expression plasmids. At 72 hr post-
transfection, the levels of the exogenous hTDP-43 and mTDP-43 proteins
were compared by Western blotting with use of anti-Myc. The mouse
Hsp70 and tubulin were analyzed as the internal control. The means of
the relative levels obtained from three independent experiments (S.D.)
are plotted in the lower 2 panels, with the level of the exogenous
hTDP-43 in cells with the transfection dose of 20 μg plasmid DNA/ 106
cells as 100. The differences in the relative levels of the Myc-tagged
hTDP-43 or mTDP-43 among the variants were assessed by the ANOVA
test. Note the similar levels of hTDP-43-Myc and mTDP-43-Myc at each
dose of the expression plasmid(s) used.
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